Last reviewed · How we verify
Tegoprazan 50 mg
Tegoprazan 50 mg is a Potassium-Competitive Acid Blocker (P-CAB) Small molecule drug developed by First People's Hospital of Hangzhou. It is currently FDA-approved. Also known as: K-CAB, K-cab.
Tegoprazan is a potassium-competitive acid blocker (P-CAB) that inhibits the H+/K+-ATPase enzyme, reducing gastric acid secretion.
Tegoprazan 50 mg is a small molecule that blocks the potassium-transporting ATPase, a mechanism that is classified as a blocker. It has been studied in clinical trials for the eradication of Helicobacter pylori infection.
At a glance
| Generic name | Tegoprazan 50 mg |
|---|---|
| Also known as | K-CAB, K-cab |
| Sponsor | First People's Hospital of Hangzhou |
| Drug class | Potassium-Competitive Acid Blocker (P-CAB) |
| Target | H+/K+-ATPase |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Tegoprazan competes with potassium ions for binding to the H+/K+-ATPase enzyme, which is located on the luminal surface of parietal cells in the stomach. This competitive inhibition prevents the exchange of hydrogen ions for potassium ions, thereby reducing the secretion of gastric acid.
Approved indications
Pipeline indications
Common side effects
- Headache
- Diarrhea
- Nausea
- Dizziness
- Constipation
Key clinical trials
- Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial (NA)
- Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (NA)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy (PHASE4)
- Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication (PHASE2, PHASE3)
- Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori） (PHASE4)
- Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia (PHASE4)
- Clinical Trial for the Comparative Evaluation of Acid Suppression and Symptom Management of Gastroesophageal Reflux Disease With the Administration of Tegoprazan or Pantoprazole (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tegoprazan 50 mg CI brief — competitive landscape report
- Tegoprazan 50 mg updates RSS · CI watch RSS
- First People's Hospital of Hangzhou portfolio CI
Frequently asked questions about Tegoprazan 50 mg
What is Tegoprazan 50 mg?
How does Tegoprazan 50 mg work?
Who makes Tegoprazan 50 mg?
Is Tegoprazan 50 mg also known as anything else?
What drug class is Tegoprazan 50 mg in?
What development phase is Tegoprazan 50 mg in?
What are the side effects of Tegoprazan 50 mg?
What does Tegoprazan 50 mg target?
Related
- Drug class: All Potassium-Competitive Acid Blocker (P-CAB) drugs
- Target: All drugs targeting H+/K+-ATPase
- Manufacturer: First People's Hospital of Hangzhou — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Also known as: K-CAB, K-cab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing